Hosted on MSN2d
Eli Lilly to Acquire Scorpion Therapeutics' Breast Cancer Candidate For up to $2.5 Billion
Eli Lilly (LLY) agreed to acquire an experimental treatment for breast cancer and other advanced solid tumors from Scorpion Therapeutics for up to $2.5 billion. The purchase price includes an upfront ...
gut.bmj7d
Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour control
Background The immune suppression mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unknown, but preclinical ...
Nature26d
Charging the batteries to heal wounds through PI3K
A new study shows that manipulation of these electric fields affects wound healing in vivo and identifies the phosphoinositide 3-kinase signaling pathway as a key component of cell migration in ...
Nature5y
Infinity and Intellikine to develop oral PI3K inhibitors for inflammatory diseases
Infinity Pharmaceuticals has gained access to Intellikine's portfolio of phosphoinositide 3-kinase-δ (PI3Kδ) and PI3Kγ inhibitors for inflammation and oncology indications through an exclusive ...
Verastem (VSTM) Gets a Buy from Mizuho Securities
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Verastem (VSTM – Research Report) today and set a price target of $9.00.